Skip to main content
These products are not intended to diagnose, treat, cure, or prevent any disease. Research compounds are sold for laboratory and educational purposes only.
These products are not intended to diagnose, treat, cure, or prevent any disease. Research compounds are sold for laboratory and educational purposes only.
Nasal - CJC-1295 10mg

Nasal – CJC-1295 10mg

$149.00

523 in stock

523 in stock

  • Name:
    CJC-1295 (tetrasubstituted Growth Hormone–Releasing Hormone analog)
  • Sequence:
    Tyr–D-Ala–Asp–Ala–Ile–Phe–Thr–Asn–Ser–Tyr–Arg–Lys–Val–Leu–Ala–Gly–Gln–Leu–Ser–Ala–Arg–Lys–Leu–Leu–Gln–Asp–Ile–Met–Ser–Arg–Gln–Gln–Gly–Glu–Ser–Asn–Gln–Glu–Gln–His–Ala–Val–Ser–Ser–Tyr–Arg–Ala–Leu–Gly–Ser–Leu–Gln–Asp–Ile–Leu–Asn–Ser–NH₂
  • Molecular Formula:
    C₁₅₂H₂₅₂N₄₄O₄₂
  • Molecular Weight:
    ≈ 3367.9 g/mol
  • CAS Registry Number:
    863288-34-0

CJC-1295 – RESEARCH-GRADE PEPTIDE ANALOG FOR GROWTH HORMONE–RELEASING HORMONE (GHRH) AND PITUITARY AXIS STUDIES

Scientific Overview of CJC-1295

CJC-1295 is a synthetic, long-acting analog of Growth Hormone–Releasing Hormone (GHRH 1-29) engineered to increase the stability and duration of growth hormone (GH) stimulation in biological research models.

CJC-1295 serves as a model compound for studying pituitary regulation, GH-IGF-1 signaling dynamics, and endocrine pulse modulation in vivo and in vitro.

Key Research Areas

• Pituitary Function and GH Pulse Dynamics – investigation of prolonged GH and IGF-1 elevation through GHRH receptor agonism and peptide stabilization (Teichman et al., 2006).
• Endocrine Axis Regulation – study of feedback loops within the hypothalamic–pituitary–somatotropic (HPS)system, including somatostatin and ghrelin interactions.
• Metabolic and Lipolytic Signaling – exploration of GH-mediated effects on lipid metabolism, glucose balance, and protein synthesis in metabolic research.
• Peptide Engineering and Half-life Extension – evaluation of DAC conjugation for pharmacokinetic modeling and sustained receptor activation.

Mechanistic Overview

CJC-1295 binds to GHRH receptors on pituitary somatotrophs, triggering cAMP-dependent GH release.

Unlike native GHRH, the DAC modification allows extended circulation (t½ ≈ 6–8 days in animal models), enabling studies on long-term GH pulse amplitude, IGF-1 synthesis, and receptor desensitization.

The peptide’s structure makes it ideal for exploring controlled endocrine stimulation and protein–peptide conjugation technologies.

Research Applications
• GH/IGF-1 Axis Characterization
• Endocrine Pulse Frequency Analysis
• Receptor Agonist and Analog Design Studies
• Metabolic and Anabolic Pathway Investigation

CJC-1295 provides a reliable experimental framework for examining long-acting GHRH analogs, hormonal pulsatility, and metabolic regulation mechanisms within peptide endocrinology.

COAs

COA_Nasal_CJC-1295_CJC10N1125

*This peptide is intended solely for laboratory research use. It is not approved for human consumption or therapeutic application.

Skip to content